These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30056180)

  • 1. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
    Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P; Kawalec P; Pilc A
    Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
    Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
    Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
    Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
    Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
    Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
    Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.
    Bodger K; Kikuchi T; Hughes D
    Aliment Pharmacol Ther; 2009 Aug; 30(3):265-74. PubMed ID: 19438428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
    Vasudevan A; Ip F; Liew D; van Langenberg DR
    Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
    Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
    J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
    J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C; Selinger CP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.